Dermatologicals
Refine Search
Biotechnology
New research has been published in the Journal of Allergy and Clinical Immunology (JACI) that shows treatment with amlitelimab, an anti-OX40 ligand antibody, significantly reduced symptoms of atopic dermatitis (AD) and was maintained even after treatment stopped. 9 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted a Rare Pediatric disease designation for BPM31510T, an investigational treatment for epidermolysis (EB) from BPGbio. 4 November 2024
Pharmaceutical
Denmark’s privately-held dermatology specialist LEO Pharma and Japan’s Kyowa Kirin have revealed that they will terminate the distribution and co-promotion agreement for the psoriasis vulgaris treatment Dovobet Ointment, Gel, and Foam (calcipotriol hydrate / betamethasone dipropionate) in Japan on December 31, 2024. 1 November 2024
Biotechnology
Regeneron Pharmaceuticals today announced financial results for the third quarter of 2024 that beat expectations, but still saw its share price fall more than 6% to $866 in early trading. 31 October 2024
Biotechnology
Treatment with Tremfya (guselkumab) resulted in clear or almost clear skin in the majority of adults with low body surface area (BSA) moderate plaque psoriasis (PsO) with special site involvement who had failed topical treatment, says US healthcare giant Johnson & Johnson. 25 October 2024
Biotechnology
New results show Eli Lilly Ebglyss (lebrikizumab-lbkz) improved skin (including hand and face) and itch among patients with moderate-to-severe atopic dermatitis (eczema) who were previously treated with Dupixent (dupilumab). 25 October 2024
Biosimilars
Iceland-based Alvotech and the US unit of Israel’s of Teva Pharmaceutical Industries today revealed that that the US Food and Drug Administration (FDA) has approved Selarsdi (ustekinumab-aekn) in a new presentation 22 October 2024
Pharmaceutical
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
The US Food and Drug Administration (FDA) has approved a 2mL pre-filled syringe and pre-filled autoinjector, each containing 320mg of Belgian drugmaker UCB’s Bimzelx (bimekizumab-bkzx), to treat psoriasis. 14 October 2024
Biosimilars
Bio-Thera Solutions and Hungary’s Gedeon Richter have reached an exclusive commercialization and license agreement. 14 October 2024
Biotechnology
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Pharmaceutical
Beijing’s InnoCare Pharma has announced encouraging Phase II results for its novel TYK2 inhibitor, ICP-488, aimed at treating moderate-to-severe plaque psoriasis. 10 October 2024
Biotechnology
With its recent US Food and Drug Administration (FDA) approval, Eli Lilly’s Ebglyss (lebrikizumab) adds a new competitor to the atopic dermatitis (AD) market. 8 October 2024
Pharmaceutical
The European Medicines Agency’s pharmacovigilance committee, PRAC, has started a review of medicines containing finasteride and dutasteride following concerns regarding suicidal ideation (suicidal thoughts) and behaviors. 4 October 2024
Generics
Aspire Pharma, a UK-based niche generics business, has announced the acquisition of all assets from Canute Pharma, further expanding its product range. 4 October 2024
Pharmaceutical
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Biotechnology
US biotech major Amgen rolled out senior executives and a swish presentation in providing an update on two of its drugs in Phase III trials this week. 26 September 2024
Pharmaceutical
LEO Pharma has presented late-breaking data on the DELTA FORCE trial for Anzupgo (delgocitinib) cream as a potential treatment for adult patients with moderate to severe chronic hand eczema (CHE). 26 September 2024
Biotechnology
Belgian drugmaker UCB (Euronext: UCB) has announced the presentation of new four-year data in patients with moderate to severe plaque psoriasis treated with bimekizumab, the company’s IL-17A and IL-17F inhibitor that is marketed as Bimzelx. 25 September 2024
Biotechnology
Belgian biotech BCI Pharma has appointed Didier Malherbe as chairman of the board of directors. 6 July 2020
Pharmaceutical
Privately-held Danish medical dermatology specialist LEO Pharma today announced that Dr Monica Shaw and Nathalie Joannes will join the executive leadership team adding seasoned experience and international profile to the company. 1 July 2020
Pharmaceutical
French drugmaker Sanofi has certainly been on a public relations drive this year, using every chance possible to show off the progress of its pipeline and its investments in innovation and manufacturing. 24 June 2020
Biotechnology
China’s National Medical Products Administration (NMPA) has approved Dupixent (dupilumab) for moderate-to-severe atopic dermatitis in adults whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. 19 June 2020
Biotechnology
Chicago-based AbbVie has released positive data from the Phase III MEASURE UP 1 study of Rinvoq (upadacitinib) in moderate to severe atopic dermatitis. 18 June 2020
Biotechnology
Janssen has announced new long-term plaque psoriasis data for Tremfya (guselkumab), a first-in-class treatment showing consistent, high levels of skin clearance at week 100 and week 204 (four years) in adult patients with moderate to severe plaque psoriasis. 15 June 2020
Biotechnology
The European Medicines Agency has validated the marketing authorization application (MAA) for tralokinumab, an investigational product for the treatment of adult patients with moderate-to-severe atopic dermatitis (AD) under development by privately-held Danish dermatology specialist LEO Pharma. 12 June 2020
Generics
51 states and territories in the USA have banded together to accuse 26 drugmakers of drug price fixing. 11 June 2020
Biotechnology
Danish dermatology specialist LEO Pharma has promised a plethora of data from Phase III trials in atopic dermatitis (AD) and psoriasis at this year’s American Academy of Dermatology (AAD) virtual meeting later this month. 2 June 2020
Biotechnology
Regeneron and Sanofi have presented new data on the PD-1 inhibitor Libtayo (cemiplimab-rwlc) from a pivotal Phase II trial in advanced cutaneous squamous cell carcinoma (CSCC), the deadliest non-melanoma skin cancer. 1 June 2020
Pharmaceutical
Spanish drugmaker Almirall has teamed up with the University Carlos III Madrid (UC3M) and the MEDINA Foundation, and they have launched a project to find new treatments for recessive dystrophic epidermolysis bullosa and other genetic diseases caused by nonsense mutations. 28 May 2020
Biotechnology
The US Food and Drug Administration has approved a label extension for Dupixent (dupilumab), to include treatment of children aged six to 11 with moderate-to-severe atopic dermatitis (AD). 27 May 2020
Biotechnology
New York-based biotech firm Hoth Therapeutics has obtained exclusive worldwide licensing rights to the BioLexa Platform, an antimicrobial therapy focused on treating atopic dermatitis. 18 May 2020
Biotechnology
While targeted therapies have delivered on their promise to make oncology more personalized, the addition of immunotherapy agents without first testing for patients who are most likely to benefit may limit the success of triplet combinations in melanoma. 14 May 2020
Pharmaceutical
Switzerland-based Galderma today announced results of DREAM (Dysport Real-world Evaluation and Measured satisfaction study), a clinical study of Dysport (abobotulinumtoxinA) for Injection that evaluated patient satisfaction and safety with a twice-yearly treatment schedule. 12 May 2020
Pharmaceutical
Spanish drugmaker Almirall looked set to close trading on Monday at around 5% lower in the stock market. 11 May 2020
Biotechnology
Amgen’s Otezla (apremilast), a drug divested by Celgene ahead of its acquisition by Bristol-Myers Squibb, could soon be approved in a new indication after the presentation of new data. 6 May 2020
Biotechnology
Investors in Regeneron could afford a rare smile in these difficult times, as the company’s first quarter results came in on Tuesday, sending shares 7% higher by midday. 5 May 2020
Biotechnology
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics have announced positive top-line data from the Phase III KALM-2 study of Korsuva (CR845/difelikefalin). 21 April 2020
Pharmaceutical
Danish dermatology specialist LEO Pharma has singed a worldwide licensing deal with Taiwan-based Oneness Biotech and China’s Microbio Shanghai for the development and commercialization of the novel atopic dermatitis (AD) and allergic asthma drug candidate FB825. 15 April 2020
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze